Saturday 17 October 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 55.9% and free cash flow fell 30.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
37.19
1.01
−2.64%
Follow EWTX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 13.19 | 5.41 | 5.12 | 9.00 | 10.60 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 40.49 | 20.71 | 12.46 | 38.12 | 30.48 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 19 | 31 | 59 | 88 | 110 | 146 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | (17) | (43) | (68) | (100) | (134) | (168) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | (17) | (43) | (68) | (100) | (134) | (168) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | (8) | (10) | (5) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (23.17) | (1.14) | (1.27) | (1.57) | (1.45) | (1.63) | |||||
| Cash flow | — | — | — | — | (19.80) | (0.89) | (0.98) | (1.44) | (1.18) | (1.40) | |||||
| Capex | — | — | — | — | (0.27) | (0.02) | (0.10) | (0.09) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | — | (20.08) | (0.91) | (1.09) | (1.53) | (1.19) | (1.40) | |||||
| Book value | — | — | — | — | 171.58 | 7.31 | 6.47 | 5.00 | 4.97 | 5.07 | |||||
| Shares, m | — | — | — | — | 1 | 38 | 54 | 64 | 92 | 103 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (15) | (34) | (53) | (92) | (109) | (144) | ||||
| Capex | — | — | — | — | 0 | (1) | (6) | (6) | (1) | 0 | |||||
| Free cash flow | — | — | — | — | (15) | (34) | (58) | (98) | (110) | (144) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 125 | 273 | 340 | 310 | 452 | 516 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | (129) | (281) | (352) | (318) | (470) | (530) | |||||
| Shareholders’ equity | — | — | — | — | 127 | 274 | 347 | 319 | 459 | 522 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (26.11) | (20.56) | (20.74) | (28.33) | (32.37) | (32.29) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (16,355.41) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | (14.21) | (35.53) | (21.78) | (30.10) | (34.40) | (34.19) | |||||
Negative figures in brackets.
Charts ten years each
Edgewise Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics, Inc. | $4.6B | — (loss-making) | — | — | n/m | −78.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DNTH Dianthus Therapeutics, Inc. | $4.2B | — (loss-making) | — (loss-making) | +294.30% (above 0%: growing) | n/m | −105.37% (below 0%: shrinking) | 100.00% | (8,079.11%) | Compare |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | — (loss-making) | — | — | n/m | −30.24% (below 0%: shrinking) | 0.00% | 0.00% | |
| ABCL AbCellera Biologics Inc. | $4.1B | — (loss-making) | — (loss-making) | −76.29% (below 0%: shrinking) | n/m | +151.98% (above 0%: growing) | 100.00% | (1,550.05%) | Compare |
| LEGN Legend Biotech Corporation Sponsored ADR | $3.8B | — (loss-making) | 112× | +51.90% (above 0%: growing) | n/m | −26.79% (below 0%: shrinking) | 64.54% | 14.37% | Compare |
| TNGX Tango Therapeutics, Inc. | $3.8B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −4.58% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RLAY Relay Therapeutics, Inc. | $3.8B | — (loss-making) | — (loss-making) | −95.44% (below 0%: shrinking) | n/m | +2.13% (above 0%: growing) | 100.00% | (25,949.71%) | Compare |
| ARQT Arcutis Biotherapeutics, Inc. | $3.7B | 131× | 196× | +59.33% (above 0%: growing) | n/m | +227.96% (above 0%: growing) | 91.58% | 12.65% | Compare |
| TLX Telix Pharmaceuticals Limited | $3.6B | — | — | — | — | −44.78% (below 0%: shrinking) | — | — | Compare |
| Median of peers | $3.8B | — | — | −12.19% | — | −15.69% | 91.58% | 0.00% |
Edgewise Therapeutics, Inc. (EWTX) key facts
- Concern: Edgewise Therapeutics, Inc. reported a net loss of $167.8 million, or a loss of $1.63 per share, for fiscal 2025.
- Edgewise Therapeutics, Inc. (EWTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, EWTX traded at $37.19, a market capitalization of $4.2 billion.
- Return on equity was −34.2% and debt-to-equity 0.00.